

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNEVISION HOLDINGS LTD.
新意網集團有限公司
(the “Company”)
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1686)

**CHANGES OF DIRECTORS
AND
APPOINTMENT OF NOMINATION COMMITTEE MEMBER**

The board of Directors of the Company (the “Board”) announces that:-

1. Ms. LAU Yeuk-hung, Fiona (“**Ms. Lau**”) has tendered her resignation as a Non-Executive Director of the Company with effect from 15 April 2025;
2. Professor Jack LAU (“**Professor Lau**”) has been re-designated from an Independent Non-Executive Director to a Non-Executive Director of the Company with effect from 15 April 2025; and
3. Dr. CHAN Chun-kwong, Jane (“**Dr. Chan**”) has been appointed as an Independent Non-Executive Director of the Company and a member of the Nomination Committee of the Board, both with effect from 15 April 2025.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Lau has tendered her resignation as a Non-Executive Director of the Company with effect from 15 April 2025 in order to devote more time to attend to her role as an executive director and the chief executive officer of SmarTone Telecommunications Holdings Limited. Ms. Lau has served on the Board as an Executive Director of the Company since October 2019 and subsequently re-designated as a Non-Executive Director of the Company in February 2023.

Ms. Lau has confirmed that she has no disagreement with the Board and there are no other matters with respect to her resignation that need to be brought to the attention of the holders of the securities of the Company.

The Board would like to express its gratitude to Ms. Lau for her valuable contributions to the Company during her tenure of office.

RE-DESIGNATION OF DIRECTOR

The Board also announces that Professor Lau has been re-designated from an Independent Non-Executive Director to a Non-Executive Director of the Company with effect from 15 April 2025 (the “**Re-designation**”).

Professor Lau, aged 57, has been an Independent Non-Executive Director of the Company since 19 April 2024. He received his Bachelor’s and Master’s degrees in Electrical Engineering and Computer Sciences from the University of California, Berkeley, and obtained his Ph.D. degree in Electrical and Electronic Engineering from The Hong Kong University of Science and Technology (“**HKUST**”) in 1994. Professor Lau then continued his post-doctoral research at Stanford University and completed his Executive Master of Business Administration program of Northwestern University Kellogg-HKUST in 2010.

Professor Lau is an Adjunct Professor of the Department of Electronic and Computer Engineering at HKUST and also a Court member of HKUST. He is the President of Qatar Science and Technology Park.

Professor Lau was a member of the Appeal Tribunal Panel (Buildings) of the Development Bureau of the Government of the Hong Kong Special Administrative Region and the Listing Committee of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Professor Lau was awarded the Ten Outstanding Young Persons in Hong Kong (2000), Young Industrialist Award of Hong Kong (2005), Excellence in Achievement of World Chinese Youth Entrepreneurs Award (2009) and Ernst & Young Entrepreneur Of The Year China (Technology) (2009). He was bestowed an Honorary Fellowship at HKUST and honoured with the Directors Of The Year Award by the Hong Kong Institute of Directors in 2010 and 2011 respectively.

A consultancy company wholly-owned and controlled by the spouse of Professor Lau will be engaged by the group company(ies) of Sun Hung Kai Properties Limited (“**SHKP**”), the substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “**SFO**”), for the provision of consultancy services on or after 15 April 2025.

Save as disclosed above, Professor Lau (i) did not hold any other directorships in the last three years in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other position in the Company and its subsidiaries; and (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company.

As at the date of this announcement, Professor Lau does not have, and is not deemed to have, any interests in the shares or underlying shares of the Company within the meaning of Part XV of the SFO.

Professor Lau received an appointment letter from the Company for his appointment as an Independent Non-Executive Director on 19 April 2024, which is amended by a new appointment letter for his role as a Non-Executive Director of the Company. He will be subject to retirement by rotation and re-election at annual general meetings of the Company in

accordance with the amended and restated articles of association of the Company (the “**Articles of Association**”). Professor Lau continues to be entitled to a director’s fee of HK\$150,000 per annum (or a pro rata amount for the duration of his directorship for an incomplete year) for being a Director of the Company. His director’s fee is fixed by the Board while his annual salary, if any, is determined by the Board from time to time with reference to his contribution in terms of time, effort and his expertise and is reviewed on an annual basis, and the sum of discretionary bonus, if any, is determined by the Board at its absolute discretion having regard to the operating results of the Company, its subsidiaries and its associated companies from time to time and the performance of the Director.

The Board would like to take this opportunity to thank Professor Lau for his valuable contributions to the Company and looks forward to his continuous support to the Company in his new role within the Board.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that Dr. Chan has been appointed as an Independent Non-Executive Director of the Company and a member of the Nomination Committee of the Board, both with effect from 15 April 2025 (the “**Appointment**”).

Dr. Chan, aged 69, received her B.A. from Yale University and M.D. from The University of Chicago. She has been registered as a medical practitioner in Hong Kong since 1993 and has been in private practice since 2005. Dr. Chan was elected as a Fellow by Hong Kong College of Physicians and as a Fellow of the Hong Kong Academy of Medicine (Medicine), both in 1993. She is a specialist in Respiratory Medicine.

Dr. Chan has been the President of the Hong Kong Chinese Medical Association Limited since 2021, the President of the Hong Kong Chinese Medical Association Foundation Limited since 2024 and an Honorary Clinical Associate Professor of the Department of Medicine of The University of Hong Kong since 1995.

Dr. Chan is the spouse of Professor Wong Yue-chim, Richard, an independent non-executive director of SHKP.

Save as disclosed above, Dr. Chan (i) did not hold any other directorships in the last three years in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other position in the Company and its subsidiaries; and (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

As at the date of this announcement, Dr. Chan does not have, and is not deemed to have, any interests in the shares or underlying shares of the Company within the meaning of Part XV of the SFO.

There is no service contract entered into between the Company and Dr. Chan. She will receive an appointment letter from the Company for her appointment as an Independent Non-Executive Director and a member of the Nomination Committee of the Board of the Company. Dr. Chan will hold office until the first annual general meeting of the Company after her appointment and shall be eligible for re-election in accordance with the Articles of Association. Thereafter, she will be subject to retirement by rotation and re-election at annual general meetings of the

Company in accordance with the Articles of Association. Dr. Chan is entitled to receive a director's fee of HK\$175,000 per annum (or a pro rata amount for the duration of her directorship for an incomplete year) for being a Director of the Company and a member of the Nomination Committee of the Board. Her director's fee is fixed by the Board while her annual salary, if any, is determined by the Board from time to time with reference to her contribution in terms of time, effort and her expertise and is reviewed on an annual basis, and the sum of discretionary bonus, if any, is determined by the Board at its absolute discretion having regard to the operating results of the Company, its subsidiaries and its associated companies from time to time and the performance of the Director.

Dr. Chan was found by The Medical Council of Hong Kong (the "MCHK") to have contravened the Code of Professional Conduct published by the MCHK for (i) the publication of certain promotional statements and/or information; and (ii) the quotation of certain qualifications and appointments on her website during the period from about 2014 to 2016. The MCHK accepted that Dr. Chan did not promote her professional practice and services deliberately and acknowledged that Dr. Chan had an unblemished and distinguished career serving the medical profession and volunteered in public services for many years. The MCHK made an order in 2020 that Dr. Chan's name be removed for the General Register for a period of one month and the operation of the removal order be suspended for a period of six months.

Dr. Chan has confirmed that (i) she has satisfied the criteria for independence set out in Rule 3.13(1) to (8) to the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

The Board would like to take this opportunity to welcome Dr. Chan in joining the Board.

Save as disclosed above, there are no other matters concerning the Re-designation and/or the Appointment that need to be brought to the attention of the holders of the securities of the Company nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

By order of the Board
SUNEVISION HOLDINGS LTD.
Bonnie LAU
Company Secretary

Hong Kong, 15 April 2025

As at the date of this announcement, the Board comprises four Executive Directors, being KWOK Ping-luen, Raymond, FUNG Yuk-lun, Allen, TUNG Chi-ho, Eric and CHAN Man-yuen, Martin; six Non-Executive Directors, being CHEUNG Wing-yui, KWOK Kai-wang, Christopher, David Norman PRINCE, SIU Hon-wah, Thomas, CHAN Hong-ki, Robert and Jack LAU; and five Independent Non-Executive Directors, being LI On-kwok, Victor, KING Yeo-chi, Ambrose, WONG Kai-man, LEE Wai-kwong, Sunny and CHAN Chun-kwong, Jane.